Project Grant R13HL182316
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $5K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, DC 20036, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $294,023 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Heartlung Corporation to develop the AUTOCHAMBER AI tool. AUTOCHAMBER is designed to opportunistically screen existing chest CT scans for early detection of enlarged cardiac chambers and left ventricular hypertrophy, which can indicate risk of atrial fibrillation, stroke, and heart failure. The project...
- This Project Grant award of $142,870 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports Emory University's investigation into the multi-level determinants of inequities in end-of-life care for adults with heart failure. The key objectives are to: Characterize the influence of individual and hospital-level factors on end-of-life heart failure care through hierarchical multiple regression analysis. Quantify the impact of neighborhood-based...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $190,080 to the Ann & Robert H. Lurie Children's Hospital of Chicago to develop and pilot a cardiovascular health (CVH) screening and primary care referral program called "Champion Fathers" for expectant fathers. The key objectives are to: 1) determine how the transition to fatherhood impacts CVH metrics using data from the Coronary Artery Risk...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $763,858 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System Inc.) to assess the impact of improving cardiovascular disease (CVD) care for adults with diagnosed diabetes across diverse global settings. The project, led by Dr. Jennifer Manne-Goehler and an interdisciplinary team, aims to develop the PREDICT-DM global...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $774,229 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Kaiser Foundation Hospitals to conduct a large longitudinal cohort study on cardiometabolic outcomes among adolescents and young adults (AYA). The goal is to better understand the epidemiology of cardiometabolic conditions like hypertension, prediabetes, and fatty liver disease in AYA populations, identify high-risk groups, and inform early...
- The National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH), awarded a $699,133 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The project aims to investigate the molecular insights into the actions of SGLT2 inhibitors and GLP1 agonists across the heart,...
- This $499,103 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports Alleviant Medical, Inc. in two key efforts: Implementing high-volume manufacturing capabilities and establishing production readiness for the ALV1 system, a novel transcatheter approach to relieve left atrial pressure in heart failure patients without requiring a cardiac implant. Executing reimbursement and marketing initiatives to...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research grant program (CFDA 93.837), awarded $793,956 to Resuscitation Innovations LLC, doing business as Advancedcpr Solutions LLC, for the project "HEAD UP CPR AND AORTIC OCCLUSION TO IMPROVE SURVIVAL AFTER REFRACTORY CARDIAC ARREST". This project grant, awarded on January 1, 2025 with a planned completion date of January 23, 2026, aims to develop and evaluate new treatments to improve...
- This federal Project Grant award of $708,678, provided by the National Heart, Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to conduct a Sequential Multiple Assignment Randomized Trial (SMART) to reduce food insecurity and improve adherence in patients with hypertension. The key products and services to be delivered under this grant include: Determining the most effective initial food insecurity intervention (resource information or community health worker...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $165,672 to New York University School of Medicine to conduct research aimed at increasing heart transplant (HT) volume in the United States. The key objectives are to: Investigate the impact of donor risk factors, such as coronary artery disease, left ventricular dysfunction, and older age, on post-HT outcomes using European and U.S. registry data. This...